Is TECH a good stock to buy?
Bio-Techne Corporation · end-of-day data as of Nov 13, 2026
- P/E vs own-16.7%
- MAs4 of 4
- MACD0.01
- Sector▲ +15.9%
- Earnings in81d
- P/E66.2x
- RSI65
- Support-1.5%
- Resistance+5.9%
- Off 52w high-0.1%
- Volume0.8x
- Bollingerupper half
- News0.00
- FCF yield+2.7%
- ConsensusHold · 13
- Trendsideways
- 52w range$43–$73
- ATR+0.2%
- Off ATH-46.5%
- InsidersNone in 90d
- PT$67.18 -7.7%
- P/E vs sector+105.4%
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Bio-Techne a good stock to buy?
Bio-Techne is strong on 2 of the 5 questions about the business. The price is about usual: 66.2 times its earnings, near its 3-year median of 72.1 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage hard to copy
- Economics profitable
- Execution mixed
- Fragility sturdy
- Price about usual
TECH sales growth revenue growth
+2%a year, for the last 3 yearsBio-Techne's sales grew 2% a year for 3 years, to $1.22B in fiscal 2026.
TECH analysts' forecast revenue estimates
+5%the sales they expect next fiscal year, on the lastAnalysts expect Bio-Techne's sales to grow 5% to $1.27B in fiscal 2027 (9 analysts).
TECH return on capital ROIC
pretickt analysis11%earned before tax on the money invested in itBio-Techne earned 11% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Alnylam 31%, Incyte 29%, CRISPR Therapeutics -24% and Twist Bioscience -31%.
TECH margin on each sale gross margin
66%left after making the productBio-Techne kept 66% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 65%.
TECH margin after costs profit margin
20%of sales left after running the businessBio-Techne's operating margin was 20% in the 12 months to Sep 30, 2026, against 26% in fiscal 2023.
TECH cash generated free cash flow
$308Mcash left after investing, last 12 monthsBio-Techne generated $308M of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.
TECH earnings vs estimates
5 of 8quarters above the analysts' estimateBio-Techne beat the analysts' profit estimate in 5 of its last 8 quarters, the latest on Nov 6, 2026.
TECH insider selling
-$437Ksold, net, by its executives in 12 monthsBio-Techne's executives and directors sold a net $437K of shares in the 12 months to Nov 13, 2026; none bought.
TECH number of employees
-3%fewer people in a yearBio-Techne had 3,000 employees at the end of fiscal 2026, 3% fewer than a year before.
TECH CEO pay
$8.15Mfor fiscal 2025, 72% of it in stock and optionsBio-Techne paid its CEO $8.15M for fiscal 2025, 72% of it in stock and options.
TECH financial health Altman Z-score
16.1Altman Z-score, safe above 3Bio-Techne's Altman Z-score is 16.1 (Nov 13, 2026), above 3, where the safe zone starts.
TECH quality checks Piotroski score
7 of 9checks passedBio-Techne passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on the current ratio and sales for its assets.
TECH biggest customers
under 10%of sales from any one customerNo customer made 10% of Bio-Techne's sales in fiscal 2026.
TECH in past recessions
pretickt analysis+3%its sales in the worst oneBio-Techne's sales grew through each of the last 2 US recessions (2008–09 and 2020).
TECH price vs profit P/E ratio
66.2×a year's earningsBio-Techne's P/E ratio is 66.2 (Nov 13, 2026), near its 3-year median of 72.1.
TECH price vs competitors
pretickt analysis66.2×a year's earnings, against its competitorsInvestors pay 66.2 times Bio-Techne's earnings (Nov 13, 2026), more than for Incyte (64.3) or Alnylam (8.3).
TECH analysts' target price target
-8%to their average targetAnalysts' average price target for Bio-Techne is $67.18, 8% below the Nov 13, 2026 close of $72.80.
TECH growth priced in fair value
pretickt analysis+15%a year, for ten years, to be worth the priceAt $72.80 a share, Bio-Techne's free cash flow must grow about 15% a year for ten years to be worth the price (Nov 13, 2026).
What is Bio-Techne's P/E ratio?
Bio-Techne's P/E ratio is 66.2 (Nov 13, 2026), near its 3-year median of 72.1. Investors pay 66.2 times Bio-Techne's earnings (Nov 13, 2026), more than for Incyte (64.3) or Alnylam (8.3).
Who are Bio-Techne's biggest competitors?
pretickt compares Bio-Techne with Twist Bioscience, Alnylam, Incyte and CRISPR Therapeutics. Bio-Techne's sales grew 1% in the 12 months to Sep 30, 2026, faster than CRISPR Therapeutics (-33%), slower than Alnylam (+56%), Incyte (+25%) and Twist Bioscience (+22%).
Is Bio-Techne profitable?
Bio-Techne's operating margin was 20% in the 12 months to Sep 30, 2026, against 26% in fiscal 2023. Bio-Techne generated $308M of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.
Are insiders selling Bio-Techne stock?
Bio-Techne's executives and directors sold a net $437K of shares in the 12 months to Nov 13, 2026; none bought.
Who owns Bio-Techne stock?
617 institutions report more than all of Bio-Techne's shares, 113% on Jun 30, 2026 (shares lent out count twice); Vanguard, BlackRock and Fidelity added shares that quarter.
How many employees does Bio-Techne have?
Bio-Techne had 3,000 employees at the end of fiscal 2026, 3% fewer than a year before.
Who are Bio-Techne's biggest customers?
No customer made 10% of Bio-Techne's sales in fiscal 2026.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.